A Phase I, Open-Label, Single Centre Study Designed to Determine the Absolute Bioavailability of ABT-450 (150 mg) and ABT-267 (25 mg) When Administered as an Oral Co-Formulated Product With Ritonavir (100 mg), ABT 450/r/ABT 267, to Healthy Adult Subjects
Latest Information Update: 19 Apr 2014
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors AbbVie
- 17 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Feb 2014 New trial record